10 completed. 10 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Completed 10 |
Follow Mucinoses: new trials by email Literature Review of Mucinoses trials Research Report on Mucinoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India Elaprase - Hunter Syndrome | Phase 4 | Completed | Takeda | 5 | 2022-04-21 | 2025-01-23 |
| China Post-marketing Surveillance (PMS) Study of Aldurazyme® Laronidase - Mucopolysaccharidosis I | Phase 4 | Completed | Genzyme, a Sanofi Company | 12 | 2021-10-28 | 2025-09-17 |
| Awareness in Old Aged Patients During Laryngoscopy and Intubation Using Isolated Forearm Technique Sevoflurane, TIVA - Awareness, Anesthesia, Recall Phenomenon | Phase 4 | Completed | Ain Shams University | 50 | 2021-09-05 | 2022-01-13 |
| Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Elaprase for intravenous (IV) infusion - Hunter Syndrome | Phase 4 | Completed | Shire | 21 | 2015-10-28 | 2026-04-02 |
| Pregabalin and Colonic Function Pregabalin, Placebo, Bowel preparation - Healthy | Phase 4 | Completed | Mayo Clinic | 62 | 2010-03-01 | 2012-03-07 |
| Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial curcumin, placebo - Irritable Bowel Syndrome | Phase 4 | Completed | Kaiser Permanente | 17 | 2008-11-01 | 2015-03-11 |
| Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Idursulfase - Hunter Syndrome, Mucopolysaccharidosis II | Phase 4 | Completed | Shire | 28 | 2007-12-31 | 2021-06-08 |
| A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI Naglazyme - Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome | Phase 4 | Completed | BioMarin Pharmaceutical | 4 | 2006-05-01 | 2011-07-22 |
| A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease Aldurazyme (Recombinant Human Alpha-L-Iduronidase) - Mucopolysaccharidosis I, Hurler's Syndrome | Phase 4 | Completed | Genzyme, a Sanofi Company | 34 | 2004-12-01 | 2015-04-03 |
| A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients laronidase - Mucopolysaccharidosis I, Hurler's Syndrome | Phase 4 | Completed | Genzyme, a Sanofi Company | 25 | 2004-07-01 | 2014-05-05 |
Mucopolysaccharidosis I (3) · Mucopolysaccharidosis II (3) · Mucopolysaccharidosis IV (3) · Abdominal Pain (1) · Constipation (1) · Diarrhea (1) · Intraoperative Awareness (1) · Irritable Bowel Syndrome (1) · Lysosomal Storage Diseases (1) · Mucopolysaccharidosis VI (1) · Pain (1) · Respiratory Aspiration (1) · Sudden Infant Death (1)
Carbohydrate Metabolism, Inborn Errors (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Connective Tissue Diseases (10) · Genetic Diseases, Inborn (10) · Metabolic Diseases (10) · Metabolism, Inborn Errors (10) · Mucopolysaccharidoses (10) · Nutritional and Metabolic Diseases (10) · Skin and Connective Tissue Diseases (10) · Lysosomal Storage Diseases (9) · Neurologic Manifestations (5) · Pathological Conditions, Signs and Symptoms (4) · Genetic Diseases, X-Linked (3) · Heredodegenerative Disorders, Nervous System (3)
Iduronidase (3) · idursulfase (3) · Cathartics (1) · Curcumin (1) · Golytely (1) · Pregabalin (1) · Sevoflurane (1) · galsulfase (1)
Genzyme, a Sanofi Company (3) · Shire (2) · Ain Shams University (1) · BioMarin Pharmaceutical (1) · Kaiser Permanente (1) · Mayo Clinic (1) · Takeda (1)
United States (5) · Brazil (2) · Canada (1) · China (1) · Dominican Republic (1) · Egypt (1) · France (1) · Germany (1) · India (1) · Malaysia (1) · Philippines (1) · Poland (1) · Portugal (1) · Serbia (1) · Taiwan (1)
Celeste Decker, MD (1) · Michael Camilleri, MD (1)
PMID 21596994, PMID 22393902, PMID 24108527, PMID 25902842, PMID 33775523, PMID 41163043
1RC1DK086182 (1), 2014 (1), R01DK067071 (1), R01DK079866 (1), UL1RR024150 (1)